Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107027 | 0.81 | EGLN2 (0.36) | EGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL3491362 | 0.79 | PTPN1 (0.35) | PTPN1F10HSD11B1 | |
| SCHEMBL19260907 | 0.77 | EGLN2 (0.38) | EGLN2EGLN1EGLN3P4HTM | |
| SCHEMBL123714 | 0.76 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL29626875 | 0.74 | PTPN1 (0.59) | PTPN1F10HSD11B1 | |
| SCHEMBL2021014 | 0.74 | PTPN1 (0.59) | PTPN1F10HSD11B1 | |
| SCHEMBL2025216 | 0.73 | PTGES (0.43) | PTPN1F10HSD11B1 | |
| SCHEMBL107026 | 0.72 | — | — | |
| SCHEMBL3490389 | 0.70 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL3491226 | 0.69 | CES2 (0.40) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | PTPN1 3492/4885F10 551/4885HSD11B1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.